** Pfizer PFE.N said on Tuesday it would generate $1.7 billion more in savings from cost cuts to its manufacturing and research operations, as the drugmaker expects to be an "earnings growth" story over the next three years
** Median PT of brokerages covering the stock is $28 - data compiled by LSEG
ENCOURAGING COMMENTARY
** BMO Capital Markets ("outperform", PT: "$30") says outperformance this quarter (particularly on the cost side) positions Pfizer well for the rest of the year, derisking the company's forecast amid a tumultuous economic backdrop
** Jefferies (PT:$32) says PFE reported an ok Q1, adding the company's oncology drugs will start to resonate with investors
** Leerink Partners ("market perform") says the company had encouraging comments on tariffs, dividend and M&A
** J.P.Morgan (PT:$30) believes stronger new launch performance and/or further progress on the drugs in development will be necessary to significantly change the current narrative on the stock, which the brokerage sees as more likely from 2026
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。